Why Gland Pharma is at All Time Low? | 3 Reasons for Gland Pharma Fall

Founded by Chinese Promoter Fosun Pharma, Gland Pharma is one of the biggest injectible players listed in the Indian Markets.Gland Pharma Limited, a generic injectable-focused company, engages in the development, manufacture, sale, and distribution of pharmaceuticals. The company’s primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others.

It offers its products for various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, as well as anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, vitamins/minerals/nutrients, and others.

Since July 2021, the stock of gland pharma has been falling due to various reasons. In this video we shall understand the fundamental factors behind the fall of Gland Pharma.


0:00 Introduction
0:22 Structure of video
0:43 Gland pharma at 52 week low
2:14 Financial Issues
7:27 Operational issues
9:35 Governance issues

Complete Fundamental Stock Analysis Tool - Stock-o-meter:
https://investyadnya.in/stock-o-meter

Research Based Ready-made Model Portfolios:
https://investyadnya.in/model-portfolios

Comprehensive Mutual Fund Reviews:
https://investyadnya.in/fund-o-meter

Yadnya Books and eBooks now available:
On Amazon - https://amzn.to/2XKtlks
On our website - https://investyadnya.in/books

Find us on Social Media and stay connected:
Blog - https://blog.investyadnya.in
Telegram - http://t.me/InvestYadnya
Facebook Page -   / investyadnya  
Facebook Group - https://goo.gl/y57Qcr
Twitter -   / investyadnya  
LinkedIn -   / investyadnya  

#glandpharma #stockmarketnews
#InvestYadnya #YIA

LEGAL DISCLAIMER:

Use of this information is at the user's own risk. The Company and its directors, associates and employees will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided herein. The investment discussed or views expressed herein may not be suitable for all investors. The users should rely on their own research and analysis and should consult their investment advisors to determine the merit, risks and suitability of recommendation. Past performance is not a guarantee for future performance or future results. Information herein is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The images used may be copyright of the company or third party. As a condition to using the services, the user agrees to the terms of use of the website and the services.


DISCLOSURES UNDER SEBI (RESEARCH ANALYST) REGULATIONS, 2014:

Yadnya Academy Pvt. Ltd. (InvestYadnya) is registered with SEBI under SEBI (Research Analyst) Regulations, 2014 with registration no. INH000008349.
Disclosure with regard to ownership and material conflicts of interest
1. Neither Research Analyst nor the entity nor his associates or relatives have any financial interest in the subject Company;
2. Neither Research Analyst nor the entity nor its associates or relatives have actual / beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report or date of public appearance;
3. Neither Research Analyst nor the entity nor its associates or his relatives have any other material conflict of interest at the time of publication of the research report or at the time of public appearance.
Disclosure with regard to receipt of Compensation
1. The Research Entity and its associates have not received compensation from the subject company in the past twelve months.
2. The subject company is not or was not a client during the twelve months preceding the date of recommendation.